NICE says no to Takeda's Mepact
This article was originally published in Scrip
Executive Summary
NICE, the health technology institute for England and Wales, has again said it will not be recommending Takeda's Mepact (mifamurtide) for young bone cancer patients because of the drug's high cost and uncertainty over how much extra benefit the drug offers compared with current treatment.